64 related articles for article (PubMed ID: 19860591)
1. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study.
Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
Immunol Invest; 2009; 38(8):820-38. PubMed ID: 19860591
[TBL] [Abstract][Full Text] [Related]
2. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study.
Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
Immunol Invest; 2010; 39(6):570-86. PubMed ID: 20653425
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
4. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
6. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
7. [Cytotoxicity of cytotoxic T lymphocytes induced by keratin 19-sensitized dendritic cells against MCF-7 cells in vitro].
Li MF; Luo RC; You CX; Tu XY
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1247-50. PubMed ID: 16234100
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
[TBL] [Abstract][Full Text] [Related]
11. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
12. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
13. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
14. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Kitsukawa K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
[TBL] [Abstract][Full Text] [Related]
15. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
16. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
18. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
20. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
